Last close As at 05/08/2026
SEK6.71
▲ −0.16 (−2.33%)
Market capitalisation
SEK435m
Research: Healthcare
Immunicum has announced that it has signed a collaboration and supply agreement with Pfizer and Merck KGaA, Darmstadt, Germany for the checkpoint inhibitor (CPI) Bavencio to be used in combination with ilixadencel in the Phase Ib/II ILIAD study. Bavencio (avelumab) is marketed by Pfizer and Merck KGaA, and approved in the US and EU. The availability of Bavencio at no cost to Immunicum in the ILIAD study potentially opens up European study sites, which will be aided by the recent share issues.
Written by
Immunicum |
Collaboration and supply agreement signed |
Agreement signed |
Pharma & biotech |
19 November 2018 |
Share price performance
Business description
Next events
Analyst
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Immunicum has announced that it has signed a collaboration and supply agreement with Pfizer and Merck KGaA, Darmstadt, Germany for the checkpoint inhibitor (CPI) Bavencio to be used in combination with ilixadencel in the Phase Ib/II ILIAD study. Bavencio (avelumab) is marketed by Pfizer and Merck KGaA, and approved in the US and EU. The availability of Bavencio at no cost to Immunicum in the ILIAD study potentially opens up European study sites, which will be aided by the recent share issues.
Year end |
Revenue (SEKm) |
PBT* |
EPS* |
DPS |
P/E |
Yield |
12/17 |
0.0 |
(80.3) |
(3.1) |
0.0 |
N/A |
N/A |
12/18e |
0.0 |
(95.9) |
(1.9) |
0.0 |
N/A |
N/A |
12/19e |
0.0 |
(266.8) |
(2.9) |
0.0 |
N/A |
N/A |
12/20e |
0.0 |
(56.9) |
(0.6) |
0.0 |
N/A |
N/A |
Note: *PBT and EPS are as reported.
Icing on the cake
Building on a very busy summer, which included stock issues and agreement on the ILIAD study protocol with the FDA, Immunicum has now announced a collaboration and supply agreement with Pfizer and Merck KGaA for the CPI Bavencio (avelumab) to be used in combination with ilixadencel. We had already removed the cost of CPI supply from our model, but the endorsement by Pfizer and Merck KGaA makes expansion of the ILIAD study to European centres (where CPIs are not readily available) possible, and thus recruitment of the Phase II portion could be faster than we had estimated. Bavencio was approved by the FDA in March 2017 for metastatic Merkel cell carcinoma (MCC), and for urothelial carcinoma in May 2017. Bavencio was approved for metastatic MCC in the EU in September 2017. Before Immunicum’s announcement, the PD-L1 monoclonal antibody was in 18 combination studies in 2017, four of which were immunoncology (I/O) combination studies.
Funding secured
Immunicum has secured funding for its clinical programmes until the end of 2021. The EGM on 8 November resolved to approve both resolutions on the directed and rights issues, and we had already included the number of shares issued, the subsequent SEK351m cash inflow and an estimated 10% share issue costs in our FY18 numbers. The rights and share issues are expected to complete on or around 13 December.
Valuation: Unchanged, but confidence higher
The signing of a collaboration agreement with Pfizer and Merck KGaA should give investors confidence that big pharma lends ilixadencel a significant endorsement as a combination I/O agent, otherwise the partners would sell a valuable CPI commercially. Our valuation remains unchanged at SEK1.4bn or SEK15.1 per share.
Exhibit 1: Financial summary
|
|
|
SEK'000s |
2017 |
2018e |
2019e |
2020e |
2021e |
Year end 31 December |
|
|
IFRS |
IFRS |
IFRS |
IFRS |
IFRS |
|
INCOME STATEMENT |
|
|
|
|
|
|
|
|
Revenue |
|
|
|
0 |
0 |
0 |
0 |
0 |
EBITDA |
|
|
|
(80,629) |
(95,804) |
(266,846) |
(56,904) |
(59,571) |
Operating expenses |
|
|
(80,847) |
(96,017) |
(267,080) |
(57,162) |
(59,854) |
|
Depreciation |
|
|
|
(71) |
(61) |
(3) |
(1) |
(0) |
Operating income |
|
|
218 |
213 |
234 |
258 |
283 |
|
Reported operating profit |
|
|
(80,700) |
(95,865) |
(266,849) |
(56,905) |
(59,571) |
|
Net Interest |
|
|
|
362 |
(15) |
6 |
(13) |
7 |
Profit before tax (reported) |
|
|
(80,338) |
(95,880) |
(266,843) |
(56,918) |
(59,563) |
|
Reported tax |
|
|
|
0 |
0 |
0 |
0 |
0 |
Profit after tax (reported) |
|
|
(80,338) |
(95,880) |
(266,843) |
(56,918) |
(59,563) |
|
Minority interests |
|
|
0 |
0 |
0 |
0 |
0 |
|
Net income (reported) |
|
|
(80,338) |
(95,880) |
(266,843) |
(56,918) |
(59,563) |
|
Basic average number of shares outstanding |
|
25,959 |
49,444 |
92,258 |
92,258 |
92,258 |
||
EPS - basic reported (SEK) |
|
|
(3.09) |
(1.94) |
(2.89) |
(0.62) |
(0.65) |
|
BALANCE SHEET |
|
|
|
|
|
|
|
|
Non Current Assets |
|
|
105,309 |
6 |
3 |
2 |
1 |
|
Property Plant and equipment, net |
|
69 |
5 |
2 |
1 |
0 |
||
Other financial assets |
|
|
1 |
1 |
1 |
1 |
1 |
|
Other Non Current Assets |
|
|
105,239 |
0 |
0 |
0 |
0 |
|
Current Assets |
|
|
140,837 |
423,533 |
156,929 |
100,313 |
40,838 |
|
Cash and cash equivalents |
|
|
128,883 |
416,881 |
150,093 |
93,284 |
33,606 |
|
Accounts receivable |
|
|
0 |
3,675 |
3,859 |
4,052 |
4,254 |
|
Marketable securities and short-term investments |
0 |
0 |
0 |
0 |
0 |
|||
Prepaid expenses |
|
|
8,454 |
2,977 |
2,977 |
2,977 |
2,977 |
|
Current Liabilities |
|
|
55,740 |
15,214 |
15,449 |
15,750 |
15,838 |
|
Accounts payable |
|
|
11,714 |
842 |
1,077 |
1,378 |
1,466 |
|
Accrued other liabilities |
|
|
43,694 |
13,081 |
13,081 |
13,081 |
13,081 |
|
Other current liabilities |
|
|
331 |
1,291 |
1,291 |
1,291 |
1,291 |
|
Non Current Liabilities |
|
|
850 |
850 |
850 |
850 |
850 |
|
Long term debt |
|
|
850 |
850 |
850 |
850 |
850 |
|
Equity |
|
|
|
189,556 |
409,577 |
142,734 |
85,816 |
(30,666) |
Retained earnings start of period |
|
(151,447) |
(231,785) |
(327,664) |
(594,507) |
(708,344) |
||
Total Shareholder's Equity |
|
|
189,556 |
409,577 |
142,734 |
85,816 |
(30,666) |
|
CASH FLOW |
|
|
|
|
|
|
|
|
Cash Flow from Operations |
|
|
|
|
|
|
|
|
EBIT (Operating profit) |
|
|
(80,700) |
(95,865) |
(266,849) |
(56,905) |
(59,571) |
|
Depreciation |
|
|
|
71 |
62 |
3 |
1 |
0 |
Income Tax paid |
|
|
0 |
0 |
0 |
0 |
0 |
|
Other Working Capital changes |
|
34,455 |
(37,316) |
51 |
108 |
(115) |
||
Cash interest paid |
|
|
(274) |
(15) |
(26) |
(26) |
0 |
|
Cash interest received |
|
|
0 |
0 |
32 |
13 |
7 |
|
Net cash used in Operating activities |
|
(46,447) |
(133,140) |
(266,788) |
(56,809) |
(59,678) |
||
Cash Flow from Investing |
|
|
|
|
|
|
|
|
Purchase of fixed assets |
|
|
0 |
0 |
0 |
0 |
0 |
|
Sale of Investments |
|
|
10,162 |
0 |
0 |
0 |
0 |
|
Net cash used in investing activities |
|
10,162 |
0 |
0 |
0 |
0 |
||
Cash Flow from Financing |
|
|
|
|
|
|
|
|
Change in Capital Stock |
|
|
62,269 |
421,139 |
0 |
0 |
0 |
|
Net cash from Financing activities |
|
62,269 |
421,139 |
0 |
0 |
0 |
||
Net Changes in Cash and Cash Equivalent |
|
25,984 |
287,999 |
(266,788) |
(56,809) |
(59,678) |
||
Cash and Cash Equivalents - Beginning |
|
102,899 |
128,883 |
416,882 |
150,094 |
93,285 |
||
Cash and Cash Equivalents - End |
|
128,883 |
416,882 |
150,094 |
93,285 |
33,607 |
||
Net cash/(debt) |
128,033 |
416,031 |
149,243 |
92,434 |
32,756 |
|||
Source: Company accounts, Edison Investment Research
|
|
Research: Healthcare
EyeGate reported data in its Ocular Bandage Gel (OBG) studies in punctate epitheliopathies (PE) and in corneal wound healing following bilateral photorefractive keratectomy (PRK) surgery. The PRK study showed improved wound healing and the PE trial showed improvement in patient symptoms. EyeGate will meet with the FDA to discuss whether the existing data are sufficient for a 510(k) de novo regulatory filing.